GM2-gangliosidosis, AB variant
GM2-gangliosidosis, AB variant is a rare lysosomal storage disorder that falls under the broader category of GM2 gangliosidosis. This genetic disorder is characterized by the accumulation of GM2 gangliosides in the neurons due to a deficiency in the GM2 activator protein, which is essential for the degradation of GM2 gangliosides by the enzyme beta-hexosaminidase A.
Pathophysiology[edit | edit source]
The GM2-gangliosidosis, AB variant, is caused by mutations in the GM2A gene located on chromosome 5q33.1. The GM2A gene encodes the GM2 activator protein, which is necessary for the proper function of beta-hexosaminidase A. In the absence of functional GM2 activator protein, GM2 gangliosides accumulate within the lysosomes of neurons, leading to progressive neurodegeneration.
Clinical Features[edit | edit source]
Patients with GM2-gangliosidosis, AB variant, typically present with symptoms in infancy or early childhood. Common clinical features include:
Diagnosis[edit | edit source]
The diagnosis of GM2-gangliosidosis, AB variant, is based on clinical presentation, biochemical testing, and genetic analysis. Enzyme assays can demonstrate deficient activity of beta-hexosaminidase A in the presence of normal beta-hexosaminidase B activity. Genetic testing can confirm mutations in the GM2A gene.
Treatment[edit | edit source]
Currently, there is no cure for GM2-gangliosidosis, AB variant. Treatment is primarily supportive and focuses on managing symptoms and improving the quality of life. This may include:
- Anticonvulsants for seizure control
- Physical therapy to manage spasticity and maintain mobility
- Occupational therapy to assist with daily activities
- Speech therapy for communication difficulties
Prognosis[edit | edit source]
The prognosis for individuals with GM2-gangliosidosis, AB variant, is generally poor. The disease is progressive, and most affected individuals do not survive beyond early childhood.
Related Pages[edit | edit source]
- GM2 gangliosidosis
- Tay-Sachs disease
- Sandhoff disease
- Lysosomal storage disorder
- Beta-hexosaminidase
- Genetic disorder
Categories[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD